Print Friendly, PDF & Email

Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia

Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia Topline Results Expected First Half of 2021 December 16, 2020 07:00 AM Eastern Standard Time NEW YORK–(BUSINESS WIRE)–Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the first set of…